Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

Author(s): Kevin Kalinsky, MD, MS1; Melissa K. Accordino, MD, MS2; Codruta Chiuzan, PhD3; Prabhjot S. Mundi, MD2; Elizabeth Sakach, MD1; Claire Sathe, MD2; Heejoon Ahn, MS3; Meghna S. Trivedi, MD, MS2; Yelena Novik, MD4; Amy Tiersten, MD5; George Raptis, MD6; Lea N. Baer, MD7; Sun Y. Oh, MD8; Amelia B. Zelnak, MD9; Kari B. Wisinski, MD10; Eleni Andreopoulou, MD11; William J. Gradishar, MD12; Erica Stringer-Reasor, MD13; Sonya A. Reid, MD14; Anne O’Dea, MD15; Ruth O’Regan, MD16; Katherine D. Crew, MD, MS2; and Dawn L. Hershman, MD, MS2
Source: DOI: 10.1200/JCO.22.02392 Journal of Clinical Oncology 41, no. 24 (August 20, 2023) 4004-4013.
Maem Hussein MD

Dr. Maen Hussein's Thoughts

Would you keep treating with CDK4/6 inhibitors and just switch endocrine therapy after failing first line ET+CDK4/6 inhibitor? This trial says YES.

PURPOSE

Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) improves progression-free survival (PFS) and overall survival (OS) in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer (MBC). Although preclinical and clinical data demonstrate a benefit in changing ET and continuing a CDK4/6i at progression, no randomized prospective trials have evaluated this approach.

METHODS

In this investigator-initiated, phase II, double-blind placebo-controlled trial in patients with HR+/HER2– MBC whose cancer progressed during ET and CDK4/6i, participants switched ET (fulvestrant or exemestane) from ET used pre-random assignment and randomly assigned 1:1 to the CDK4/6i ribociclib versus placebo. PFS was the primary end point, defined as time from random assignment to disease progression or death. Assuming a median PFS of 3.8 months with placebo, we had 80% power to detect a hazard ratio (HR) of 0.58 (corresponding to a median PFS of at least 6.5 months with ribociclib) with 120 patients randomly assigned using a one-sided log-rank test and significance level set at 2.5%.

RESULTS

Of the 119 randomly assigned participants, 103 (86.5%) previously received palbociclib and 14 participants received ribociclib (11.7%). There was a statistically significant PFS improvement for patients randomly assigned to switched ET plus ribociclib (median, 5.29 months; 95% CI, 3.02 to 8.12 months) versus switched ET plus placebo (median, 2.76 months; 95% CI, 2.66 to 3.25 months) HR, 0.57 (95% CI, 0.39 to 0.85); P = .006. At 6 and 12 months, the PFS rate was 41.2% and 24.6% with ribociclib, respectively, compared with 23.9% and 7.4% with placebo.

CONCLUSION

In this randomized trial, there was a significant PFS benefit for patients with HR+/HER2– MBC who switched ET and received ribociclib compared with placebo after previous CDK4/6i and different ET.

Author Affiliations

1Winship Cancer Institute, Emory University, Atlanta, GA;2Columbia University Irving Medical Center, New York, NY;3Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY;4New York University Perlmutter Cancer Center, NYU Langone Health, New York, NY;5Icahn School of Medicine at Mount Sinai, New York, NY;6Zucker School of Medicine—Northwell Cancer Institute, Lake Success NY;7State University of New York at Stony Brook, Stony Brook, NY;8Montefiore Medical Center, Bronx, NY;9Northside Hospital, Atlanta, GA;10University of Wisconsin Carbone Cancer Center, Madison, WI;11Weill Cornell Medicine, New York, NY;12Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL;13University of Alabama, Birmingham, Birmingham, AL;14Vanderbilt University Medical Center, Nashville, TN;15University of Kansas Medical Center, Westwood, KS;16University of Rochester Medical Center, Rochester, NY

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial

This is a 10-year follow-up of the ShortHER study using nine weeks vs. 12 months of adjuvant trastuzumab in HR+ non-metastatic breast cancer. With long-term follow-up, non-inferiority could not be claimed statistically. Still, the DFS/OS results are identical in those patients with N0-N3 disease, while those with N4 disease seemed to have a significant difference favoring 12 months of therapy, suggesting that volume/burden of disease drives the margin of benefit in adjuvant trastuzumab therapy.

Read More »

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

This is another option for HR positive patients after failing hormonal therapy, with an acceptable toxicity profile. Patients were HER-2 negative. (The study does not indicate if patients were HER-2 low.) It will be interesting to see how this will fair in this population now that there is another option with Enhrtu. Interesting though, patients without visceral metastases did better with chemotherapy.

Read More »